Search

Search Constraints

Start Over Filtering by: Keyword MCL-1 Remove constraint Keyword: MCL-1

Search Results

  • Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
  • Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
  • Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
  • Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting
  • The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells
  • ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib
  • A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
  • Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer
  • A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
  • Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax